Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) (iStopMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03815279
Recruitment Status : Not yet recruiting
First Posted : January 24, 2019
Last Update Posted : May 14, 2019
Sponsor:
Collaborators:
Amgen
Celgene
University of Iceland
Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
Landspitali University Hospital

Brief Summary:
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Smoldering Multiple Myeloma Drug: Carfilzomib Drug: Lenalidomide Drug: Dexamethasone Phase 2

Detailed Description:
This is an open label, single center, phase II study assessing the efficacy of treating patients with intermediate-risk smoldering myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide and treating patients with high risk SMM and active multiple myeloma (MM) with combinational therapy with dexamethasone, lenalidomide and carfilzomib. Patients that are eligible for this study are participants in the IstopMM study (ClinicalTrials.gov number, NCT03327597) that are diagnosed with intermediate or high-risk SMM or active MM.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: An investigator initiated, academic, non-randomized, open-label phase 2 study that will assess carfilzomib, lenalidomide and dexamethasone regimen as treatment in patients with intermediate-risk (not carfilzomib) or high-risk SMM or active MM.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Estimated Study Start Date : May 2019
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2028


Arm Intervention/treatment
Experimental: High-risk SMM and MM

Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.

Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.

Maintenance (1 year):

Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks.

Drug: Carfilzomib
Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
Other Name: Kyprolis

Drug: Lenalidomide
Lenalidomide PO once daily on days 1-21 of a 28 day cycle
Other Name: Revlimid

Drug: Dexamethasone
Dexamethasone will be administered weekly
Other Name: Dexasone

Experimental: Intermediate-risk SMM

Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.

Maintenance (1 year):

Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks.

Drug: Lenalidomide
Lenalidomide PO once daily on days 1-21 of a 28 day cycle
Other Name: Revlimid

Drug: Dexamethasone
Dexamethasone will be administered weekly
Other Name: Dexasone




Primary Outcome Measures :
  1. Rate of MRD negativity [ Time Frame: 36 months after study enrollment ]
    Minimal residual disease (MRD) as determined VDJ sequencing


Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Up until 3 years after treatment ]
    Rates of progression free survival with progression being determined by IMWG response criteria

  2. Overall survival [ Time Frame: Up until 3 years after treatment ]
    Overall survival as determened by the Icelandic National Cause of Death Registry



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants that are diagnosed with MM, high- or intermediate-risk SMM in the iStopMM study will be invited to participate in this study. Each patient must meet all the following inclusion criteria to be enrolled in the study:

  1. Age more than 18 years.
  2. Active MM or
  3. Smoldering myeloma, which is untreated, as defined by: Measurable M spike OR pathological FLC ratio AND bone marrow PC% > 10%
  4. The following laboratory values obtained ≤ 30 days prior to registration

    • Calculated creatinine clearance ≥ 30mL/min (using CKD-EPI equation)
    • Absolute neutrophil count (ANC) > 1000/mm3
    • Platelet count > 75000/mm3
    • Hemoglobin ≥ 8.0 g/dL
    • Total bilirubin ≤ 1.5 x ULN
    • ALT and AST ≤ 3 x ULN
  5. Measurable disease as defined by at least one of the following:

    • Serum monoclonal protein > 1.0g/L
    • > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
    • Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio
  6. Prior therapy for the treatment of solitary plasmacytoma is permitted, but >7 days should have elapsed from the last day of radiation. NOTE: Prior therapy with clarithromycin, DHEA, anakinra, pamidronate or zoledronic acid is permitted. Any additional agents not listed must be approved by the Principal Investigator.
  7. ECOG performance status 0, 1 or 2
  8. Negative pregnancy test done ≤7 days prior to C1D1, for women of childbearing potential only.
  9. Willing to follow strict birth control measures as outlined in the protocol.
  10. Female subjects: If they are of childbearing potential, agree to one of the following:

    Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

  11. Male subjects: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: Agree to practice effective barrier contraception during the entire trial treatment period and through 90 days after the last dose of trial drug, OR Must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Willing to return to enrolling institution for follow-up during the Active Treatment Phase of the trial. Agree not to donate sperm for at least 90 days after the last dose of carfilzomib
  12. Willing to provide samples for planned research
  13. Life expectancy > 6 months

Exclusion Criteria:

  1. MGUS or low-risk smoldering myeloma.
  2. Diagnosed or treated for another malignancy ≤ 2 years before trial enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  3. If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: Pregnant women Nursing women Men or women of childbearing potential who are unwilling to employ adequate contraception (per protocol)
  4. Other co-morbidity which would interfere with subject's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease
  5. Other concurrent chemotherapy, or any ancillary therapy considered investigational.

    NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment.

  6. Peripheral neuropathy > Grade 3 on clinical examination or grade 2 with pain within 30 days prior to C1D1.
  7. Major surgery ≤14 days prior to C1D1.
  8. Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. Note: Prior to trial entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
  9. Known human immunodeficiency virus (HIV) positive.
  10. Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
  11. Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  12. Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products.

    Known allergies, hypersensitivity, or intolerance to trial drugs.

  13. Inability to comply with protocol/procedures.
  14. LVEF < 40% for patients treated with carfilzomib.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03815279


Contacts
Layout table for location contacts
Contact: Sigurdur Y Kristinsson, MD, PhD +354 5431000 sigurdyk@landspitali.is

Locations
Layout table for location information
Iceland
Landspitali University Hospital Not yet recruiting
Reykjavík, Iceland, 101
Contact: Sigurdur Y Kristinsson, PhD         
Sponsors and Collaborators
Landspitali University Hospital
Amgen
Celgene
University of Iceland
Memorial Sloan Kettering Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Sigurdur Y Kristinsson, MD, PhD Landspitali University Hospital

Layout table for additonal information
Responsible Party: Landspitali University Hospital
ClinicalTrials.gov Identifier: NCT03815279     History of Changes
Other Study ID Numbers: LSH-17-001
First Posted: January 24, 2019    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Landspitali University Hospital:
Multiple Myeloma
Smoldering Multiple Myeloma
Carfilzomib
Lenalidomide
Screening

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Smoldering Multiple Myeloma
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Hypergammaglobulinemia
Dexamethasone
Dexamethasone acetate
Lenalidomide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists